Cell and Gene Therapy Third-Party Logistics Market is expected to reach US$ 23.13 billion by 2034 from US$ 9.55 billion in 2025, with a CAGR of 10.33% from 2026 to 2034. The cell and gene therapy third-party logistics market is expected to expand significantly over the forecast period, driven by increasing commercialization of advanced therapies, specialized cold chain requirements, and expanding global biopharmaceutical supply networks.
Technological advancements are reshaping logistics operations for advanced therapies. Modern logistics providers are incorporating digital monitoring systems, GPS-enabled shipment tracking, Internet of Things (IoT) sensors, cloud-based inventory platforms, and automated temperature monitoring solutions to enhance shipment visibility and reduce operational risks. Cryogenic shipping technologies using liquid nitrogen and ultra-low temperature containers have significantly improved the safe transportation of living cells and genetic materials over long distances. Artificial intelligence and predictive analytics are also being introduced to optimize routing, minimize delivery delays, and improve operational efficiency. These innovations are helping pharmaceutical companies maintain regulatory compliance while improving supply chain reliability for high-value therapeutic products.
The market includes specialized healthcare logistics companies, cold chain service providers, courier networks, packaging manufacturers, contract logistics organizations, and biopharmaceutical service providers. Strategic collaborations between therapy developers, contract manufacturing organizations, and logistics companies are strengthening global distribution capabilities for personalized medicines. Increasing investments in advanced therapy manufacturing, expansion of clinical trials, and growing regulatory focus on product traceability continue to create new opportunities for logistics service providers. As personalized medicine becomes more widely adopted, third-party logistics companies are expected to play a critical role in supporting the commercialization and global distribution of cell and gene therapies.
In 2020, 12,000 Americans are expected to receive gene therapy or stem cell treatment; by 2030, that figure is expected to increase to nearly 340,000. In addition to the present American system, various innovative methods have been proposed to finance gene therapy treatments.
To provide access to gene therapies for rare diseases worldwide, the Department of Health - Abu Dhabi (DOH) and M42 partnered with GEMMABio Therapeutics (GEMMABio) in July 2025. Through the partnership, businesses will be able to set up specialized manufacturing and research facilities within academic research institutes in Abu Dhabi, giving access to MENA patients for state-of-the-art clinical trials.
Cell and Gene Therapy Third-Party Logistics Industry Overview
The cell and gene therapy third-party logistics market has become an essential component of the advanced therapeutics ecosystem, ensuring the safe, compliant, and timely transportation of highly sensitive biological products. Unlike conventional pharmaceuticals, cell and gene therapies require highly specialized logistics solutions because many products are patient-specific, temperature-sensitive, and have extremely limited shelf lives. Third-party logistics providers offer integrated services including cryogenic storage, temperature-controlled transportation, inventory management, packaging, customs clearance, chain-of-identity tracking, and real-time shipment monitoring. These capabilities enable manufacturers, hospitals, and research organizations to maintain product integrity throughout the supply chain while meeting stringent regulatory and quality requirements. As the number of commercialized cell and gene therapies continues to increase, specialized logistics providers are becoming indispensable partners in ensuring successful treatment delivery.Technological advancements are reshaping logistics operations for advanced therapies. Modern logistics providers are incorporating digital monitoring systems, GPS-enabled shipment tracking, Internet of Things (IoT) sensors, cloud-based inventory platforms, and automated temperature monitoring solutions to enhance shipment visibility and reduce operational risks. Cryogenic shipping technologies using liquid nitrogen and ultra-low temperature containers have significantly improved the safe transportation of living cells and genetic materials over long distances. Artificial intelligence and predictive analytics are also being introduced to optimize routing, minimize delivery delays, and improve operational efficiency. These innovations are helping pharmaceutical companies maintain regulatory compliance while improving supply chain reliability for high-value therapeutic products.
The market includes specialized healthcare logistics companies, cold chain service providers, courier networks, packaging manufacturers, contract logistics organizations, and biopharmaceutical service providers. Strategic collaborations between therapy developers, contract manufacturing organizations, and logistics companies are strengthening global distribution capabilities for personalized medicines. Increasing investments in advanced therapy manufacturing, expansion of clinical trials, and growing regulatory focus on product traceability continue to create new opportunities for logistics service providers. As personalized medicine becomes more widely adopted, third-party logistics companies are expected to play a critical role in supporting the commercialization and global distribution of cell and gene therapies.
Growth Drivers for the Cell and Gene Therapy Third-Party Logistics Market
Expansion of Cell and Gene Therapy Commercialization
The growing commercialization of cell and gene therapies is a major driver of demand for specialized third-party logistics services. Pharmaceutical and biotechnology companies are bringing an increasing number of advanced therapies from clinical development to commercial markets, creating the need for highly controlled transportation and storage solutions. Unlike conventional medicines, many of these therapies require individualized handling, strict chain-of-custody management, and rapid delivery to treatment centers. Third-party logistics providers possess the infrastructure and expertise needed to manage these complex supply chains while ensuring product integrity and regulatory compliance. As more advanced therapies receive regulatory approval, logistics requirements will continue expanding, supporting long-term market growth.Rising Demand for Advanced Cold Chain Logistics
The increasing need for ultra-low temperature transportation and cryogenic storage is significantly driving the market. Cell and gene therapies often require storage at extremely low temperatures to preserve biological viability during transportation. Specialized logistics providers offer validated packaging systems, temperature-controlled containers, continuous environmental monitoring, and emergency response capabilities that reduce the risk of product degradation. Healthcare organizations and therapy manufacturers increasingly rely on experienced logistics partners to ensure uninterrupted cold chain management throughout the distribution process. Continuous investment in cold chain technologies and infrastructure is improving shipment reliability and enabling broader commercialization of advanced biological therapies across international markets.Increasing Focus on Regulatory Compliance and Supply Chain Traceability
Stringent regulatory requirements governing advanced therapeutics are encouraging greater reliance on specialized logistics providers. Cell and gene therapy shipments require comprehensive documentation, chain-of-identity verification, chain-of-custody monitoring, and complete shipment traceability to ensure patient safety and product quality. Third-party logistics companies are implementing digital tracking platforms, electronic documentation systems, and real-time monitoring technologies that support compliance with international regulatory standards. These capabilities help pharmaceutical companies minimize operational risks while ensuring transparency throughout the supply chain. As regulatory expectations continue evolving, logistics providers offering integrated compliance solutions are expected to experience increasing demand from therapy developers and healthcare organizations.Challenges in the Cell and Gene Therapy Third-Party Logistics Market
Complex Transportation and Storage Requirements
One of the primary challenges facing the market is the complexity of transporting and storing advanced therapeutic products. Cell and gene therapies are highly sensitive biological materials that require strict temperature control, specialized packaging, and continuous monitoring throughout transit. Even minor deviations in environmental conditions can compromise product quality and therapeutic effectiveness. Coordinating time-sensitive deliveries between manufacturing facilities, treatment centers, and patients also presents operational challenges. Logistics providers must maintain robust contingency plans to address transportation delays, equipment failures, and unforeseen disruptions. Successfully managing these highly specialized logistics operations requires significant investment in infrastructure, technology, and quality assurance systems.High Operational Costs and Limited Specialized Infrastructure
Providing logistics services for cell and gene therapies involves substantial operational expenses. Specialized cryogenic containers, temperature-controlled vehicles, advanced monitoring technologies, regulatory compliance systems, and highly trained personnel contribute to elevated service costs. In many regions, the availability of specialized cold chain infrastructure remains limited, creating logistical constraints for therapy distribution. Smaller healthcare providers and emerging biotechnology companies may face financial challenges in accessing premium logistics services. Expanding specialized logistics networks while maintaining cost efficiency remains a significant challenge for service providers seeking to support the growing global demand for advanced therapeutic products.United States Cell and Gene Therapy Third-Party Logistics Market
The United States represents the largest market for cell and gene therapy third-party logistics, supported by a well-established biotechnology sector, advanced healthcare infrastructure, and extensive commercialization of innovative therapies. Specialized logistics providers offer comprehensive cold chain management, cryogenic transportation, digital shipment tracking, and regulatory compliance services to pharmaceutical manufacturers and healthcare institutions. The country's strong clinical research ecosystem and growing number of approved advanced therapies continue to increase demand for sophisticated logistics solutions. Collaboration between biotechnology companies, contract manufacturers, and logistics providers is strengthening nationwide distribution capabilities. As personalized medicine continues expanding, specialized third-party logistics services will remain essential to the successful delivery of advanced therapies across the United States.In 2020, 12,000 Americans are expected to receive gene therapy or stem cell treatment; by 2030, that figure is expected to increase to nearly 340,000. In addition to the present American system, various innovative methods have been proposed to finance gene therapy treatments.
United Kingdom Cell and Gene Therapy Third-Party Logistics Market
The United Kingdom is strengthening its cell and gene therapy third-party logistics market through continued investment in life sciences, advanced manufacturing, and precision medicine initiatives. Logistics providers are expanding specialized cold chain capabilities to support the transportation of highly sensitive biological products between manufacturing facilities, research organizations, and healthcare providers. Digital supply chain management, temperature-controlled transportation, and regulatory compliance services are becoming increasingly important as advanced therapies enter routine clinical practice. Collaboration between biotechnology companies, healthcare institutions, and logistics specialists continues to improve distribution efficiency. The country's commitment to innovation and advanced healthcare supports sustained demand for specialized logistics solutions tailored to cell and gene therapies.China Cell and Gene Therapy Third-Party Logistics Market
China's cell and gene therapy third-party logistics market is expanding rapidly alongside the country's growing biotechnology industry and healthcare modernization efforts. Pharmaceutical companies are increasing investments in advanced therapies, creating greater demand for specialized logistics infrastructure capable of maintaining strict temperature control and product traceability. Logistics providers are strengthening cryogenic transportation networks, digital monitoring systems, and regulatory compliance capabilities to support expanding clinical research and commercial distribution. Government initiatives encouraging biotechnology innovation and precision medicine are further accelerating market development. As domestic manufacturing capacity and international collaborations continue to increase, demand for specialized third-party logistics services is expected to grow substantially across China.United Arab Emirates Cell and Gene Therapy Third-Party Logistics Market
The UAE is steadily developing its cell and gene therapy third-party logistics market by investing in advanced healthcare infrastructure, pharmaceutical logistics, and specialized cold chain capabilities. Healthcare providers and logistics companies are enhancing storage, transportation, and monitoring systems to support the safe handling of temperature-sensitive biological therapies. The country's strategic geographic location strengthens its role as a regional logistics hub connecting international pharmaceutical manufacturers with healthcare markets across the Middle East. Government initiatives promoting biotechnology innovation, medical excellence, and healthcare modernization are encouraging the adoption of advanced logistics solutions. As precision medicine gains greater importance and specialized therapies become more accessible, third-party logistics providers are expected to play a crucial role in supporting the UAE's evolving healthcare ecosystem.To provide access to gene therapies for rare diseases worldwide, the Department of Health - Abu Dhabi (DOH) and M42 partnered with GEMMABio Therapeutics (GEMMABio) in July 2025. Through the partnership, businesses will be able to set up specialized manufacturing and research facilities within academic research institutes in Abu Dhabi, giving access to MENA patients for state-of-the-art clinical trials.
Recent Developments in Cell and Gene Therapy Third-Party Logistics Market
- In In order to expand its skills in the life sciences and healthcare industry, DHL announced in March 2025 that it would be acquiring CryoPDP, a pharmaceutical logistics company situated in the United States. For pharmaceutical and biotech businesses, CryoPDP specializes in temperature-controlled logistics solutions, including shipping, storage, and packaging services. The goal of this acquisition is to improve DHL's supply chain services for the pharmaceutical sector.
- Advanced Therapy Connect, an industry-first integrated ordering platform created especially for cell and gene therapies under the Advanced Therapy Solutions division, was unveiled by Cardinal Health in January 2025.
Cell and Gene Therapy Third-Party Logistics Market Segments
Type
- Clinical
- Commercial
Product
- Cell Therapies
- Gene Therapies
Therapeutic Area
- Oncology
- Neurology
- Cardiovascular Diseases
- Ophthalmology
- Infectious Diseases
- Others
End Use
- Biopharmaceutical Companies
- CDMOs/CMOs
- Others
Countries
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
All the Key players have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Key Players Analysis
- Cencora Corporation
- Cardinal Health
- McKesson Corporation
- EVERSANA
- Knipper Health
- Arvato SE
- DHL
- Kuehne+Nagel
Table of Contents
1. Introduction3. Executive Summary5. Global Cell and Gene Therapy Third-Party Logistics Market14. Merger and Acquisition
2. Research Methodology
4. Market Dynamics
6. Market Share Analysis
7. Type - Historical and Current Market Trends & Forecast
8. Product - Historical and Current Market Trends & Forecast
9. Therapeutic Area - Historical and Current Market Trends & Forecast
10. End Use - Historical and Current Market Trends & Forecast
11. Countries - Historical and Current Market Trends & Forecast
12. Porter’s Five Forces Analysis
13. SWOT Analysis
15. Key Players Analysis
Companies Mentioned
- Cencora Corporation
- Cardinal Health
- McKesson Corporation
- EVERSANA
- Knipper Health
- Arvato SE
- DHL
- Kuehne+Nagel
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | June 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 9.55 Billion |
| Forecasted Market Value ( USD | $ 23.13 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
